Tian Lin-Lin, Qian Bin, Jiang Xiao-Hui, Liu Yu-Shan, Chen Tong, Jia Cheng-You, Zhou Ya-Li, Liu Ji-Bin, Ma Yu-Shui, Fu Da, Ding Sen-Tai
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China.
Department of Microbiology, Faculty of Basic Medical Sciences, Guilin Medical University, Guilin 541001, China.
Int J Genomics. 2021 Mar 16;2021:6670390. doi: 10.1155/2021/6670390. eCollection 2021.
MicroRNAs (miRNAs) have been demonstrated to exhibit important regulatory roles in multiple malignancies, including hepatocellular carcinoma (HCC). hsa-miR-497-5p was reported to involve in cancer progression and poor prognosis in many kinds of tumors. However, the expression and its clinical significance of hsa-miR-497-5p in HCC remain unclear.
In the present study, we investigated the expression of hsa-miR-497-5p in HCC and analyzed the correction of clinical features with prognosis. The expression levels of hsa-miR-497-5p and potential target genes were analyzed in HCC and adjacent noncancerous tissues using The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO) datasets. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to analyze hsa-miR-497-5p levels in 328 HCC tissues and 30 paired adjacent noncancer tissues. Overall survival (OS) and progression-free survival (PFS) of patients with HCC were assessed using the Kaplan-Meier method and the log-rank test.
The hsa-miR-497-5p expression levels were decreased, and its target genes ACTG1, CSNK1D, PPP1CC, and BIRC5 were upregulated in HCC tissues compared with normal tissues. Lower levels of hsa-miR-497-5p expression and higher levels of the four target genes were significantly associated with higher tumor diameter. Moreover, patients with lower hsa-miR-497-5p expression and higher target genes levels had shorter OS.
The expression levels of hsa-miR-497-5p may play an important regulatory role in HCC and are closely correlated with HCC progression and poor prognosis in patients. The hsa-miR-497-5p may be a specific therapeutic target for the treatment of HCC.
微小RNA（miRNA）已被证明在多种恶性肿瘤中发挥重要调节作用，包括肝细胞癌（HCC）。据报道，hsa-miR-497-5p参与多种肿瘤的癌症进展和预后不良。然而，hsa-miR-497-5p在HCC中的表达及其临床意义仍不清楚。
在本研究中，我们调查了hsa-miR-497-5p在HCC中的表达，并分析了临床特征与预后的相关性。使用癌症基因组图谱（TCGA）数据库和基因表达综合数据库（GEO）数据集分析了HCC和癌旁非癌组织中hsa-miR-497-5p及其潜在靶基因的表达水平。采用实时定量逆转录聚合酶链反应（qRT-PCR）分析328例HCC组织和30对配对癌旁非癌组织中hsa-miR-497-5p的水平。采用Kaplan-Meier法和对数秩检验评估HCC患者的总生存期（OS）和无进展生存期（PFS）。
与正常组织相比，HCC组织中hsa-miR-497-5p表达水平降低，其靶基因ACTG1、CSNK1D、PPP1CC和BIRC5上调。hsa-miR-497-5p表达水平较低和四个靶基因水平较高与肿瘤直径较大显著相关。此外，hsa-miR-497-5p表达较低和靶基因水平较高的患者OS较短。
hsa-miR-497-5p的表达水平可能在HCC中发挥重要调节作用，并且与HCC进展和患者预后不良密切相关。hsa-miR-497-5p可能是治疗HCC的特异性治疗靶点。
